$125 | Single User
$250 | Site License
$375 | Global License

GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review [Report Updated: 31-10-2018]

Published by Global Data: 31 Oct 2018 | 226001 | In Stock

Introduction

GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.

- Corporate strategy – Analyst’s summarization of the company’s business strategy.

- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.

- Company history – Progression of key events associated with the company.

- Major products and services – A list of major products, services and brands of the company.

- Key competitors – A list of key competitors to the company.

- Key employees – A list of the key executives of the company.

- Executive biographies – A brief summary of the executives’ employment history.

- Key operational heads – A list of personnel heading key departments/functions.

- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities – A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

GlaxoSmithKline Plc (GSK) is a healthcare company, which focuses on the development, manufacture and commercialization of pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of HIV, respiratory, cancer, immuno-inflammation, anti-virals, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio cover various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.

GlaxoSmithKline Plc Key Recent Developments

Oct 29,2018: GSK announces positive phase 3 results for daprodustat in patients with anaemia associated with chronic kidney disease

Oct 25,2018: GSK opens new Ellipta plant in Scotland

Oct 23,2018: MBDA, GSK and Airbus team up for Generation Stevenage event

Oct 23,2018: GlaxoSmithKline opens new £54 million facility in north-east town

Oct 22,2018: GSK invests in Montrose

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents
for GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review [Report Updated: 31-10-2018]

  • Table of Contents

    Table of Contents 3

    List of Tables 5

    List of Figures 5

    Section 1 - About the Company 6

    GlaxoSmithKline Plc - Key Facts 6

    GlaxoSmithKline Plc - Key Employees 7

    GlaxoSmithKline Plc - Key Employee Biographies 8

    GlaxoSmithKline Plc - Major Products and Services 9

    GlaxoSmithKline Plc - History 12

    GlaxoSmithKline Plc - Company Statement 38

    GlaxoSmithKline Plc - Locations And Subsidiaries 40

    Head Office 40

    Other Locations & Subsidiaries 40

    Joint Venture 53

    Section 2 – Company Analysis 55

    Company Overview 55

    GlaxoSmithKline Plc - Business Description 56

    Business Segment: Consumer Healthcare 56

    Overview 56

    Performance 56

    Key Stats 56

    Business Segment: Pharmaceuticals 57

    Overview 57

    Performance 57

    Key Stats 57

    Business Segment: Vaccines 57

    Overview 57

    Performance 58

    Key Stats 58

    Geographical Segment: International 58

    Performance 58

    Geographical Segment: The UK 58

    Performance 58

    Geographical Segment: US 58

    Performance 58

    R&D Overview 58

    GlaxoSmithKline Plc - Corporate Strategy 60

    GlaxoSmithKline Plc - SWOT Analysis 61

    SWOT Analysis - Overview 61

    GlaxoSmithKline Plc - Strengths 61

    GlaxoSmithKline Plc - Weaknesses 62

    GlaxoSmithKline Plc - Opportunities 63

    GlaxoSmithKline Plc - Threats 64

    GlaxoSmithKline Plc - Key Competitors 65

    Section 3 – Company Financial Ratios 66

    Financial Ratios - Capital Market Ratios 66

    Financial Ratios - Annual Ratios 67

    Performance Chart 70

    Financial Performance 70

    Financial Ratios - Interim Ratios 71

    Financial Ratios - Ratio Charts 72

    Section 4 – Company’s Lifesciences Financial Deals and Alliances 73

    GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 73

    GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 74

    GlaxoSmithKline Plc, Recent Deals Summary 75

    Section 5 – Company’s Recent Developments 76

    Oct 22, 2018: GlaxoSmithKline Pharmaceuticals delivers strong H1 performance; H1 Revenue up 8% and PAT higher by 21% 76

    Oct 22, 2018: GSK invests in Montrose 78

    Oct 21, 2018: GSK presents new efficacy and safety data of an anti GM-CSF antibody in patients with rheumatoid arthritis 80

    Oct 18, 2018: 18 October 2018 ViiV Healthcare submits New Drug Application to US FDA for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV Priority review voucher used with NDA submission with anticipated target action date of six mont 83

    Oct 18, 2018: 18 October 2018 ViiV Healthcare submits New Drug Application to US FDA for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV Priority review voucher used with NDA submission with anticipated target action date of six mont 92

    Oct 18, 2018: 18 October 2018 ViiV Healthcare submits New Drug Application to US FDA for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV Priority review voucher used with NDA submission with anticipated target action date of six mont 101

    Oct 18, 2018: 18 October 2018 ViiV Healthcare submits New Drug Application to US FDA for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV Priority review voucher used with NDA submission with anticipated target action date of six mont 110

    Oct 02, 2018: GSK updates policy for working with healthcare professionals 119

    Oct 02, 2018: GSK updates policy for working with healthcare professionals 120

    Oct 01, 2018: Theraflu PowerPods launches Pods For convenient cold and flu symptom relief 121

    Section 6 – Appendix 122

    Methodology 122

    Ratio Definitions 122

    About GlobalData 126

    Contact Us 126

    Disclaimer 126

List Of Tables
in GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review [Report Updated: 31-10-2018]

List of Tables

GlaxoSmithKline Plc, Key Facts 6

GlaxoSmithKline Plc, Key Employees 7

GlaxoSmithKline Plc, Key Employee Biographies 8

GlaxoSmithKline Plc, Major Products and Services 9

GlaxoSmithKline Plc, History 12

GlaxoSmithKline Plc, Other Locations 40

GlaxoSmithKline Plc, Subsidiaries 41

GlaxoSmithKline Plc, Joint Venture 53

GlaxoSmithKline Plc, Key Competitors 65

GlaxoSmithKline Plc, Ratios based on current share price 66

GlaxoSmithKline Plc, Annual Ratios 67

GlaxoSmithKline Plc, Annual Ratios (Cont...1) 68

GlaxoSmithKline Plc, Annual Ratios (Cont...2) 69

GlaxoSmithKline Plc, Interim Ratios 71

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 73

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 74

GlaxoSmithKline Plc, Recent Deals Summary 75

Currency Codes 122

Capital Market Ratios 122

Equity Ratios 123

Profitability Ratios 123

Cost Ratios 124

Liquidity Ratios 124

Leverage Ratios 125

Efficiency Ratios 125

List Of Figures, Charts and Diagrams
in GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review [Report Updated: 31-10-2018]

List of Figures

GlaxoSmithKline Plc, Performance Chart (2013 - 2017) 70

GlaxoSmithKline Plc, Ratio Charts 72

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 73

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 74

Additional Details

Publisher

Global Data

Publisher Information

Reference

226001 | GDPH4279FSA

Number of Pages

126

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
GlaxoSmithKline Partnering Deals and Alliances 2010 to 2016
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering...
01 Oct 2016 by Current Partnering USD $1,495 More Info
GlaxoSmithKline K.K. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryGlaxoSmithKline K.K. (GSK Japan) a subsidiary of GlaxoSmithKline Plc is a pharmaceutical comp...
10 Mar 2016 by Global Data USD $250 More Info
GlaxoSmithKline Pharmaceuticals Limited (GLAXO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryGlaxoSmithKline Pharmaceuticals Limited (GSK India) is a pharmaceutical company that manufact...
04 Mar 2016 by Global Data USD $250 More Info
GlaxoSmithKline Plc (GSK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryGlaxoSmithKline plc (GSK) is a healthcare company, which focuses on the development, manufact...
04 Mar 2016 by Global Data USD $250 More Info
GlaxoSmithKline Plc (GSK) - Medical Equipment - Deals and Alliances Profile
SummaryGlaxoSmithKline plc (GSK) is a healthcare company, which focuses on the development, manufact...
24 Feb 2016 by Global Data USD $250 More Info
GlaxoSmithKline Consumer Nigeria PLC (GLAXOSMITH) - Financial and Strategic SWOT Analysis Review
SummaryGlaxoSmithKline Consumer Nigeria PLC (GlaxoSmithKline Consumer Nigeria) a subsidiary of Glaxo...
09 Jan 2016 by Global Data USD $300 More Info
GlaxoSmithKline Consumer Nigeria PLC (GLAXOSMITH) - Financial and Strategic SWOT Analysis Review
SummaryGlaxoSmithKline Consumer Nigeria PLC (GlaxoSmithKline Consumer Nigeria) a subsidiary of Glaxo...
08 Nov 2015 by Global Data USD $300 More Info
Physician Views: Is GlaxoSmithKline's BRAF/MEK combo making headway in V600 mutation-positive melanoma patients?
Scope Although the clinical promise of cancer immunotherapies looks poised to see these products gai...
22 Jul 2014 by FirstWord Pharma USD $695 More Info
Physician Views: Assessing the launch of GlaxoSmithKline's Breo Ellipta
Scope It remains early in the launch, but available evidence suggests that GlaxoSmithKline's Breo El...
21 Jan 2014 by FirstWord Pharma USD $695 More Info
Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
01 Aug 2013 by FirstWord Pharma USD $695 More Info

This report is published by Global Data

Download Free Report Summary PDF

GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review [Report Updated: 31-10-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data